Background/aims: To assess the effect of long-term maintenance of steroids on HCV recurrence after liver transplantation (LT), that is still controversial, a prospective multicentre trial was conducted at the centres of Bologna and Padua, Italy.
Methods: From September 2002, 47 eligible HCV positive LT recipients were randomized to receive 2 different steroid schedules in association with tacrolimus: group A: rapid tapering and withdrawal 91 days after LT group B: slow tapering and withdrawal 25 months after LT. Thirty-nine patients were assessable: 23 in group A and 16 in group B. Donor and recipient characteristics were similar in the two groups. Median follow-up was 841 days (130-1376). One hundred liver biopsies were performed, and every patient had a biopsy at month 12.
Results: Twenty-two out of 23 (95, 65%) patients in group A and 15 out of 16 (93, 75%) in group B had histologically-confirmed HCV recurrence. Twelve-month histology showed advanced fibrosis (score 3 or 4) in 42.1% of the patients in group A versus 7.6% in group B (P=0.03). One-and 2-year advanced fibrosis-free survival were 65.2 and 60.8 in group A and 93.7% in group B (P=0.03 and =0.02, respectively).
Conclusions: Slow tapering of steroids reduced the progression of recurrent hepatitis C after LT.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jhep.2007.07.023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predicting Microvascular Invasion in Liver Transplant Recipients for Hepatocellular Carcinoma.
Cureus
December 2024
Hepatopancreatobiliary and Liver Transplant Surgery, Pakistan Kidney and Liver Institute and Research Center, Lahore, PAK.
Background: Among primary liver tumors, hepatocellular carcinoma (HCC) is considered the most common hepatic tumor. Liver transplantation is one of the curative treatment options for HCC. However, the risk of HCC recurrence after liver transplantation varies and is influenced by various factors.
View Article and Find Full Text PDFPregnancy-Related Morphea: A Case Report.
Clin Med Insights Case Rep
December 2024
Department of Obstetrics and Gynecology, School of Medicine, Reproductive Health Research Center, Guilan University of Medical Sciences, Rasht, Iran.
Background: Morphea is a skin condition marked by erythematous and hardened inflammatory lesions that can progress to atrophic and sclerotic plaques. In this case report, we present a case of a pregnant woman who showed morphea presentation.
Case Presentation: A 37-year-old GPL woman with a gestational age of 32 weeks and 2 days was referred to the hospital with complaints of swelling, pain, and erythema in both legs for the past week, without any obstetric complaints.
A Curious Case of Multimorbidity in a Patient With Goldenhar Syndrome Presenting With Vomiting.
Cureus
October 2024
Internal Medicine, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale, USA.
Goldenhar syndrome, also known as oculo-auriculo-vertebral dysplasia or hemifacial microsomia, is a rare congenital anomaly involving the first and second branchial arches. In this case report, we present a distinctive instance of a 43-year-old male with Goldenhar syndrome who presented with nausea and recurrent bilious vomiting. Initial diagnostic imaging raised concerns about pancreatitis, leading to a comprehensive evaluation that revealed gallstone pancreatitis as the cause of his symptoms.
View Article and Find Full Text PDFRenal microangiopathy induced by lenvatinib in hepatocellular carcinoma: a case report and literature review.
Front Pharmacol
November 2024
Department of Nephrology, Shanghai Changzheng Hospital, Second Military Medical University (Naval Medical University), Shanghai, China.
Lenvatinib, a multi-target inhibitor of receptor tyrosine kinases, has been increasingly used in the treatment of advanced hepatocellular carcinoma (HCC). However, its association with renal adverse effects, including proteinuria and renal microvascular complications, was not fully understood in HCC patients. We reported a case of a 68-year-old male with a history of hypertension, diabetes mellitus, and hepatitis C virus (HCV) infection, diagnosed with primary HCC in 2015.
View Article and Find Full Text PDFOutcomes of liver transplantation with donors older than 80 years in HCV patients treated with direct-action antivirals vs. non-HCV patients.
Med Clin (Barc)
November 2024
Department of Surgery, Faculty of Medicine, Complutense University, Madrid, Spain.
Background: Multiple studies have shown good results with the use of octogenarian donors in non-HCV recipients and its use is universally accepted worldwide. There are no studies analyzing differences between hepatitis C virus (HCV) and non-HCV recipients transplanted with donors≥80 years in the direct-action antivirals (DAA) period. The rate of liver transplantation (LT) using old donors is still low, and a change in the acceptance of these grafts could increase the liver pool available for LT.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!